Payment overview · 2025
General Payments
$72.31
5 reported records · 4 companies
Healthcare provider profile · identity verified
Alisha L Shoemaker, APN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · ONEIDA, TN · NPI 1003189309
Verified facts
What the public records show
CMS Open Payments records show Alisha L Shoemaker, APN received $72.31 in general payments during 2025 across 5 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 28.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.48 | 28.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.42 | 25.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.51 | 24.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.90 | 22.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $72.31 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.48 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.42 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.51 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $15.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 197 | 49 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 184 | 36 |
| Potassium Chloride | Potassium Chloride | 173 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 157 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 139 | 35 |
| Furosemide | Furosemide | 139 | 34 |
| Lisinopril | Lisinopril | 135 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 135 | 32 |
| Losartan Potassium | Losartan Potassium | 123 | 31 |
| Gabapentin | Gabapentin | 112 | 26 |
| Levothyroxine Sodium | Levothyroxine Sodium | 112 | 29 |
| Omeprazole | Omeprazole | 109 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 96 | 17 |
| Montelukast Sodium | Montelukast Sodium | 95 | 23 |
| Buspirone Hcl | Buspirone Hcl | 77 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 75 | 14 |
| Eliquis | Apixaban | 74 | 16 |
| Meloxicam | Meloxicam | 74 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 73 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 67 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 66 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 65 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 64 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | suppressed |
| Metformin Hcl | Metformin Hcl | 58 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 58 | suppressed |
| Carvedilol | Carvedilol | 56 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 56 | 15 |
| Prednisone | Prednisone | 54 | 35 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 52 | suppressed |
| Allopurinol | Allopurinol | 51 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 51 | 14 |
| Simvastatin | Simvastatin | 49 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 47 | suppressed |
| Clonazepam | Clonazepam | 46 | suppressed |
| Lorazepam | Lorazepam | 45 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 44 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 44 | suppressed |
| Ibuprofen | Ibuprofen | 44 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | suppressed |
| Sucralfate | Sucralfate | 42 | suppressed |
| Ozempic | Semaglutide | 41 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 40 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Spironolactone | Spironolactone | 36 | suppressed |
| Methocarbamol | Methocarbamol | 34 | 11 |
| Tramadol Hcl | Tramadol Hcl | 34 | suppressed |
| Anastrozole | Anastrozole | 32 | suppressed |
| Azithromycin | Azithromycin | 32 | 26 |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 30 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Bumetanide | Bumetanide | 28 | suppressed |
| Famotidine | Famotidine | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 15 |
| Dexlansoprazole Dr | Dexlansoprazole | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Alprazolam | Alprazolam | 25 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 14 |
| Roflumilast | Roflumilast | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 13 |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 16 |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Clonidine | Clonidine | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $72.31 · 5 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Auvelity, CAPLYTA, FARXIGA, VOQUEZNA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error